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Abstract There exist two paradigms about the nature of
cancer. According to the generally accepted one, cancer is a
by-product of design limitations of a multi-cellular organ-
ism (Greaves, Nat Rev Cancer 7:213–221, 2007). The
essence of the second resides in the question “Does cancer
kill the individual and save the species?” (Sommer, Hum
Mutat 3:166–169, 1994). Recent data on genetic and
epigenetic mechanisms of cell transformation summarized
in this review support the latter point of view, namely that
carcinogenesis is an evolutionary conserved phenomenon—
a programmed death of an organism. It is assumed that
cancer possesses an important function of altruistic nature:
as a mediator of negative selection, it serves to preserve
integrity of species gene pool and to mediate its evolutionary
adjustment. Cancer fulfills its task due apparently to specific
killer function, understanding mechanism of which may
suggest new therapeutic strategy.
Keywords Carcinogenesis.Mutagenesis.
Epigenetics.Programmed death of organism.
Evolutionary origin of cancer
Introduction
In scientific progress, there are periods of revolutionary
change of paradigms, i.e. of certain basic ideas (Kuhn
1970). This is what is probably taking place today in our
understanding of cancer. Strange as it may be, the huge
interest in the scientific community to the mechanisms of
carcinogenesis goes in parallel with the virtual lack of
interest to some basic questions, such as “What is cancer?
What is the nature of this phenomenon?” In only very few
studies, these questions do become an issue of discussion.
The current paradigm holds that cancer is a consequence
of internal imperfections of a multi-cellular organism, an
evidence of failure of its adaptation mechanisms: the
Darwinian evolution does not expect the future and does
not plan for it, it is compelled to operate with means that
are only available for it at present, “at hand”, which makes
compromises and restrictions inevitable (Greaves 2007).
Cancer is thereby put into the same category as other
illnesses of the old age. It is strange, but the notion of
cancer as a consequence of imperfection of the organism,
not having in fact serious justifications, has become
something self-evident.
At the same time, cancer likening to other diseases
seems arguable as it ignores one cardinal distinction. At the
heart of a “usual” illness there is a decrease in function of
the corresponding organ (irrespective of its causes). For
instance, cardiovascular diseases arise because of decrease
in the contractile functions of the heart and/or the
conducting ability of the vascular network; diabetes, due
to insufficient production of insulin; and Alzheimer’s
disease, due to infringement in nerve conduction, etc. The
general pathogenesis of these illnesses is clear, even if there
are no data on concrete molecular mechanisms.
Cancer is a different case as it involves appearance of
a previously non-existent structure (tumor), realizing a
previously non-existent function (destruction of the
organism) and rendering powerful and versatile influence
on the body. It is a question, thus, of not about a loss of
an old function, as in “usual” illnesses of the old age,
but rather about gain of a new function. Despite one-and-
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understanding what this phenomenon is, neither is there an
effective protection against it or means of combating it.
This contradiction has generated a number of new
explanations of this phenomenon (Graham 1992; Kozlov
1996; Leroi et al. 2003). The new paradigm is most clearly
expressed in the article by Sommer (1994), the very title of
which “Does cancer kill the individual and save the
species?” conveys in the implicit form its basic ideas: (1)
cancer carries out a certain function and hence is not a by-
product but a direct result of evolution; (2) the cancer’s role
is dual—being pernicious for the individual, it is necessary
for the species; (3) cancer is an altruistic phenomenon, as
price for the rescue of the species is self-destruction of the
individual. A conclusion suggests itself that the ability of
the cancer cell to kill the individual (its so-called killer
function) (Lichtenstein 2005b) is the key property, which
has determined the very appearance of this phenomenon.
The new understanding of cancer distinguishes oncology
from a number of other medical disciplines. Their purpose
is to struggle against errors of nature and restore the
normalcy (this is what the doctor does when he eliminates a
defect of a mitral valve, inserts an artificial teeth or
prescribes a hypotensive drug). Oncology, on the contrary,
is probably a unique medical discipline, which combats not
deviations from norm and mistakes of the nature, but rather
nature as such (because it struggles with a natural biological
phenomenon). In this respect, oncology is somewhat
similar to gerontology, which also struggles with a natural
phenomenon of ageing. It is perhaps for this reason that in
the both cases the struggle is so tremendously difficult.
In the recent years, new knowledge about carcinogenesis
has accumulated. The whole body of this knowledge
allows, apparently, replacing the interrogative sign in the
name of Sommer’s article with the affirmative one. In this
review, different aspects of carcinogenesis are considered
from a single point of view, namely, that carcinogenesis is
an evolutionary conserved phenomenon (a programmed
death of an organism) and serves to maintain the integrity
of the species gene pool. With this in mind, I consider in
the beginning various aspects of evolutionary origin of
cancer, such as evolutionary conservation, the Peto para-
dox, regularity of this phenomenon (“The evolutionary role
of cancer”). In “Cancer as programmed death of organism”,
the concept of cancer as programmed death of an organism
is further substantiated by showing it as the process
embracing the whole organism and unfolding along pre-
determined pathways. It is characterized by a regular and
predictable change of stages with a striking coordination of
molecular, cellular and tissue processes within the tumor/
body system. The very important moment is that the killer
function, this necessary attribute of a malignant tumor
regardless of its type, origin and localization, cannot be
explained from the accepted paradigm but fits naturally into
the alternative one. The molecular mechanisms underlying
this suicidal program are considered in “The genetics and
epigenetics of carcinogenesis”.
The evolutionary role of cancer
The evolutionary conservation of a biological phenomenon
is one of the most powerful evidences of its importance: the
stronger nature keeps its possession, the higher is its value.
Evolutionary conservation of cancer is amazing: tumors are
found not only in a multitude of now living animals (from
molluscs to mammals), but also in fossil remains of
dinosaurs of the Jurassic period (Greaves 2007; Leroi et
al. 2003). These facts alone certify for the evolutionary
value of this phenomenon.
Peto paradox and the transformation resistance of cells
The ability of cancer to affect various species of animals is a
paradoxical fact. The matter is that carcinogenesis is closely
related to cellular proliferation: due to cell divisions, accumu-
lation of mutations in the cellular genome is possible (see
below). Though the μ value (mutation rate per gene and cell
division) varies greatly (Vijg 2000), its existence and non-
zero values are evidence of this intimate link. Proliferation
and transformation are thus conjugate processes: if prolifer-
ation is sufficiently intensive, the appearance of a completely
transformed (i.e. cancer) cell is a matter of time.
This logic suggests that the probability of cancer increases
with the mass of the animal (as the number of proliferating
cells and the probability of mutations in them are higher) and
its life span. It may be assumed, therefore, that if the
resistances of animal cells to malignant transformation were
the same, blue whales (weighing more than 100 tons) would
all be suffering from cancer and disappearing as a species,
whereasmice(weightingabout20g)wouldnothavecancerat
all. In fact, however, nothing of this kind takes place: all
species (whales, mice, and man) are susceptible to cancer but
neither becomes extinct.
Explaining this so-called Peto paradox (Peto et al. 1975)
is possible by assuming an inequality of transformation
resistance of cells of various species (in whales it should be
much higher than in mice). One of the most important
determinants of the transformation resistance is the number
of stages of transformation: the greater this number, the
more strongly the individual is protected against cancer
(Frank 2004). Indeed, fibroblasts of man are much more
difficult to transform than fibroblasts of mouse because of a
greater number of mutations required for this purpose in the
former (Hahn and Weinberg 2002). Thus, the Peto paradox
(the more or less equal susceptibility to cancer of animals
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species-specific adaptation of cell transformation resistance.
If cancer had any unfavorable influence on viability of a
species, then its ousting beyond the limits of the species’
life span by means of augmentation of the transformation
resistance would be easily achieved. In one peculiar case of
the naked mole rat, in which tumors have never been
observed, this extraordinary resistance to cancer has come
about due to a relatively slight modification of regulatory
network, namely, the involvement of both p16(ink4a) and
p27(Kip1) tumor suppressors in the control of contact cell
inhibition (in human and mouse, as opposed to mole rat,
contact inhibition is triggered only by the induction of p27)
(Seluanov et al. 2009). The reason for the appearance of
such a unique trait remains unknown, but this exception to
the general rule shows that elimination of cancer, if
necessary, would present no difficulty. The susceptibility
to cancer of most animals, by the rule of contraries, is
therefore the evidence of its evolutionary usefulness.
Malignant transformation affects different species and
different tissues. The latter, too, differ in their mass and
proliferation rate and, accordingly, in transformation resis-
tance:infact,fortumorappearanceindifferenthumantissues,
different numbers of mutations are required (Renan 1993).
This is because cell type-specific differences exist in the
requirements for tumorigenic transformation (Rangarajan et
al. 2004). The fact that transformation resistance of cells is
not only species-specific but also cell type-specific indicates
that genetic as well as epigenetic mechanisms participate in
its formation.
Cancer: randomness or regularity?
The probability of appearance of a tumor in an individual is
a function of intensity of mutagenesis, which in turn is
determined by the balance of two opposite processes:
mutagenesis and anti-mutagenesis. Mutagenic factors are
subdivided, by their origin, into two types: exogenous and
endogenous. Factors from the external environment are
chemical carcinogens, ultraviolet irradiation, ionizing radia-
tion, viral and bacterial infections. This “external” component
of mutagenesis is subject to certain correction and is therefore
an important object of preventive actions.
The “intrinsic” component of mutagenesis, that cannot
be controlled at present, is caused by fundamental
processes: cell division entails inevitable errors of
replication; metabolic processes and respiration lead to
accumulation of aggressive reactive oxygen species
(ROS); telomere shortening during cell divisions results
in chromosome aberrations; spontaneous DNA depurina-
tion and methylcytosine deamination bring about DNA
damage; phagocytosis of apoptotic bodies is related to a
wide-scale natural transfection.
Mutagenesis is opposed by mechanisms of DNA repair
and apoptosis that are capable of strongly, by many orders
of magnitude, reducing mutation rate but incapable of
eliminating it completely. As a result, vital activity is
accompanied by a parallel mutagenesis and, as its conse-
quence, the organism is gradually “creeping up into
carcinogenesis” (Lichtenstein 2009). The speed of this
process, which determines the probability of appearance of
a tumor in the individual, is, as a rule, low. Thanks to that,
the majority of people throughout their life do not form
tumors (according to a saying, “not everyone lives long
enough to reach his/her cancer”). However, in about 20% of
people, the balance of counteracting forces (external and
internal mutagenesis, on the one hand, and protective
mechanisms of DNA repair and apoptosis, on the other)
develops unfavorably, the process of “creeping into
carcinogenesis” is accelerated and, as a result, cancer
overtakes the individual in, depending on the acceleration
rate, elderly or even young age (in the latter case, hereditary
genetic defects often play a key role).
Thus, the prevalent opinion on randomness of cancer,
based, first, on a relative rarity of the disease (overall, two
out of ten people suffer) and, second, on the fact that cancer
is invoked by random events (mutations), requires apparently
a certain revision. Cancer is most likely a natural, but not
inevitable, phenomenon. The same can be said about old age:
after all it is also natural but not inevitable (it is quite possible
to die young).
A completely transformed cell arises after several rate-
limiting events (mutations) affecting a number of key genes
(oncogenes and suppressor genes). The number of such
driver mutations responsible for driving the initiation,
progression, or maintenance of the tumor varies, depending
on cell origin, from 4 to 12–15 (Renan 1993; Wood et al.
2007). Mutations are rare events, and accumulation of such
a large number in one cell is hardly probable. If it
nonetheless occurs, this happens because with every
cancer-promoting mutation the cell gets some selective
advantage and forms a clone. What is improbable for a cell
is quite probable for a clone, and the bigger the clone, the
higher is the probability of the next mutation in one of the
daughter cells. The process then repeats itself. Thus,
according to the theory of multi-stage carcinogenesis, cell
transformation is a Darwinian process of consecutive cycles
of mutation–selection (Armitage and Doll 1954).
Accumulation of the mutant cells in a population is
symbolized by “the mutational pyramid”, at which base are
cells with the lowest number of cancer-promoting muta-
tions, and at the top, with the greatest (Lichtenstein 2005b).
As mutagenesis is progressing (and the mutational pyramid
grows in width and height), the transformation resistance of
the cell is depleted, thus serving as a countdown trigger. Its
full depletion in the cell, which is at the top of the pyramid
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carcinogenesis from the latent phase (in which the
“underground” of the tumor, consisting of precancerous
cells at different stages of transformation, is formed) to
an open clinical phase (when tumor becomes evident)
(Lichtenstein 2006).
An obligatory presence in eachtumorofan“underground”,
the assumption that follows from general reasoning, is
supported by discovery of “field cancerization”,i . e .l a r g ea n d
surrounding the tumor “patches” ofpartiallytransformedcells,
recognized on the basis of mutations in TP53 but remaining
undetectable by routine diagnostic techniques (Braakhuis et
al. 2003). The impossibility of defining the borders of these
fields and completely removing them during surgical
operation is, apparently, the principal cause of tumor relapse.
Mutagenesis takes placeinall cells ofthebody,and,hence,
in each tissue a mutational pyramid grows. Their growth can
be compared to sprinting on parallel lanes: all runners are
running, but the winner (in this case, who first generates a
tumor) is determined by casual circumstances. If the speed of
the leader drops for some reason, its place is taken by another
runner. This explains the so called “effect of communicating
vessels” (as it was named by a Russian physician J.I. Lorie): a
decrease in incidence of one form of cancer often does not
resultina decreaseinoverallcancerincidence—the “niche”is
filled with other forms (for instance, a drop in stomach cancer
amongthe Japanesewho movedtotheUS, iscompensated by
a riseinthe incidence oflungcancer).Thus,one can conclude
that tumor localization israndom, but its appearance isnatural
(owing to the constantly going and progressing mutagenesis).
The fact that not every individual faces an oncologic disease
during life is explained, apparently, by a prevailing mortality
from other causes.
Cancer as a guardian of gene pool
The recently proposed concept of phenoptosis (programmed
deathofanorganism)postulatesanexistenceinbiologyofthe
so-called Samurai principle (“it is better to die than to be
wrong”). The biological system is suggested to possess a
built-in self-destruction program. This program is not active
usually and comes into effect when the system begins to pose
hazard to another one, which is standing above in the
biological hierarchy (Longo et al. 2005;S k u l a c h e v1999).
The most fundamental manifestation of this altruistic
principle is apoptosis, which eliminates a cell when it begins
to be a threat for the multi-cellular community. At a signal
from the outside, the cell makes a suicide for the sake of
maintenance of the tissue homeostasis and renewal, or as a
necessary condition of morphogenesis during embryonic
development. The signal, which activates the self-destructive
program, can arise also inside the cell (e.g. in the case of
DNA damage).
If cancer is also a case of phenoptosis, a question arises,
“Which advantages does it confer to the higher hierarchical
system—to the species?” Apparently, these are the same
that apoptosis confers to the multi-cellular community,
namely, the negative selection of the hazardous individuals.
Indeed, in hereditary cancer syndromes (when the “sanitary”
role of cancer most evidently manifests itself), the tumors
appear in reproductive age and are often multiple, what does
notleavetheindividualanychanceofsurvival.Bythismeans,
germ-line mutations of functionally important genes, which
otherwise would have a high probability of spreading in the
population (Lichtenstein 2005b, Lichtenstein 2008), are
generally eliminated from the gene pool (Ponder 2001). A
computational model of cancer progression suggests that an
additional protection against cancer would lead to signifi-
cantly increased genetic predisposition to disease in the
population as a whole (Frank 2004).
The fact that cancer mainly affects individuals of old age
(>95% of total incidence) is often considered as an
argument that it is selectively neutral. Such an interpretation
raises doubts. A functionally important program, which is
active at the reproductive age, will most likely be also
active at an old age (even if it becomes useless or even
harmful), since evolutionary mechanisms that could correct
a situation, are inefficient at that age (the theory of
antagonistic pleiotropy) (Kirkwood and Austad 2000).
Thus, the high cancer incidence at advanced age can be
considered as a side effect of a program designed for
elimination of young carriers of mutant genes (the number
of such individuals is relatively low but they are potentially
quite hazardous). Cancer-related genes belong to “essential
genes” (classified as lethal by mouse knockout experi-
ments), and their mutant forms are, probably, more
detrimental to fitness than those in other genes (Thomas
et al. 2003).
Another hypothesis calling into question the general
assumption that cancer represents simply a breakdown in
normal physiology, suggests that it carries out an important
function of maintenance of optimal level of germ-line
mutagenesis. A very low mutagenesis would not provide
the variability necessary for evolution of species, while a
very high mutagenesis is fraught with many unfavorable
consequences, since for each advantageous mutation, there
are many detrimental ones. In this case, cancer is a
mechanism for negative selection, which limits the upper
level of mutagenesis and ensures an optimal mutation rate
(Sommer 1994).
And, finally, cancer perhaps fulfills the important
function of quality control at times of fast evolutionary
changes of the species, especially associated with a body
mass or life span increase, i.e. when the genome is yet
insufficiently adapted to the new conditions (such situation
arises, for example, in selective breeding of large dogs,
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(Graham 1992; Leroi et al. 2003).
Cancer as programmed death of organism
In spite of the numerous variations of the oncologic
process, its successive stages are so regular and the overall
pattern is so invariably the same that one can foresee from
the very beginning what will follow: growing tumor
aggression, inefficiency of host defense, resistance to
chemotherapy, emaciation of vital forces of the body,
metastases and death. At any level of cancer research
(clinical, cellular, or molecular), what comes first to one’s
attention is the programmed character of the unfolding
events. From theoretical point of view, cancer may be
viewed as an intrinsic robust state of the endogenous
molecular–cellular network shaped by evolution that forms
a nonlinear stochastic dynamical system with many stable
attractors in its functional landscape. The genesis and
progression of cancer are stochastic transitions between
different attractors (Ao et al. 2008).
Where lies the blame for cancer: in the cell or organism?
There are no doubts that the tumor begins from one
transformed cell: the monoclonal origin of a tumor is one
of fundamental notions of oncology. In a model system,
using a method for reconstructing cell lineage trees from
genomic variability caused by somatic mutations, it was
found that the tumor initiated from a single founder cell
(Frumkin et al. 2008). Does it mean that this first cell is to
blame for the disease and that the disease is a casual event?
Or, in other words, that carcinogenesis is a cell-autonomous
process? Most likely, the real situation is more complex.
An unexpected result of recent studies suggests that
transformation of the epithelial cells, which give rise to a
malignant tumor, is a secondary event, while the primary
changes arise in the tumor environment (Maffini et al.
2004). A rat mammary tissue recombination model and the
chemical carcinogen N-nitrosomethyl urea (NMU) were
used to determine whether the primary target of the
carcinogen is the epithelium, the stroma or both tissue
compartments. Mammary epithelial cells were exposed in
vitro either to the carcinogen or vehicle before being
transplanted into the cleared fat pads of rats exposed to
carcinogen or vehicle. Neoplastic transformation of these
mammary epithelial cells was shown to occur only when
the stroma was exposed in vivo to NMU, regardless of
whether the epithelial cells were exposed to the carcinogen.
Mammary epithelial cells exposed in vitro to the carcinogen
formed phenotypically normal ducts when injected into a
non-treated stroma. It is not known how universal is such a
sequence of events, but is doubtless that a tumor and its
environment participate in carcinogenesis as equal partners.
Throughout the long process of transformation, the cell
resides in an environment of normal neighbors and is
exposed to their influence, which could be pro- and anti-
carcinogenic. Since Virchow’s time, the association of
cancer with a chronic inflammation is well known: not
only does it always accompany tumor growth, but also very
often precedes it (Balkwill and Mantovani 2001; Coussens
and Werb 2002). Inflammatory cells secrete cytokines and
chemokines, which bind to receptors on cancer cells and
enhance their proliferation, migration and invasion.
There is evidence that carcinoma-associated fibroblasts
(CAFs), which phenotypically differ from normal fibroblasts,
possess the ability to stimulate carcinogenesis (Bhowmick et
al. 2004; Olumi et al. 1999). The loss of TGF-β responsive-
ness in fibroblasts resulted in intraepithelial neoplasia in
mouse prostate and invasive squamous cell carcinoma of the
forestomach (Bhowmick et al. 2004). A question that
remains unanswered concerns the so-called interdependent
coevolution of clonal populations of carcinoma cells and
CAFs, or, in other words, whether simultaneous generation
of two symbiotic malignancies is possible. There are
opposite opinions: some authors have found genetic alter-
ations in CAFs, whereas others consider such findings as
artifacts and deny their real existence (Allinen et al. 2004;
Campbell et al. 2009; Eng et al. 2009; Weinberg 2008). No
matter what the answer would be, one thing is clear: there are
significant distinctions between normal and cancer-
associated fibroblasts, these distinctions are heritable and
are caused by specific patterns of gene expression (Allinen et
al. 2004).
Senescent cells can also induce their normal neighbors to
carcinogenesis. The state of senescence arises from the
genotoxic stress of cells or depletion of their proliferative
potential. Senescent cells secrete myriad of factors associ-
ated with inflammation and malignancy and acting by a
paracrine mechanism. Premalignant mammary epithelial
cells exposed to senescent human fibroblasts in mice
undergo full malignant transformation. Obviously, senes-
cent cells contribute to age-related pathology, including
cancer (Coppe et al. 2008; Parrinello et al. 2005).
And, finally, conditions can exist in the body that favor
predominant survival of the mutant cells with the altered
metabolism. For example, under low-glucose conditions,
mutations in oncogene K-RAS allow colorectal cells to
outgrow their neighboring healthy cells with wild-type K-
RAS. The cells with mutant K-RAS exhibit enhanced glucose
uptake and glycolysis due to increased GLUT1 (glucose
transporter-1) expression (Yun et al. 2009).
The capabilities of the environment are not limited to
procarcinogenic effects. Tumor environment also possesses
an opposite ability, namely to reverse tumor phenotype (this
Clin Epigenet (2010) 1:85–100 89could hardly be imagined if one takes into consideration the
irreversibility of tumor-inducing mutations). Mintz and
Illmensee (1975) found that a mouse embryonic blastocyst
microenvironment suppressed the tumorigenic phenotype
of teratocarcinoma cells, which could give rise to normal
tissues. These experiments have refuted the established
notion about irreversibility of tumor phenotype. Recent
studies using various embryonic models confirmed the
earlier data, and have shown, in particular, a possibility of
reversion of the metastatic phenotype of aggressive mela-
noma cells. Nodal signaling was found to be especially
important, the inhibition of which promotes the reversion of
melanoma cells towards a melanocytic phenotype (Hendrix
et al. 2007). Some signal pathways have been identified (in
particular, the SIAH1, presenilin 1, TSAP6, and transla-
tionally controlled tumor protein, TCTP), whose activation
in tumor cells can result in the negation of genetic defects
and lead to tumor reversion. This process involves a
reprogramming mechanism using epigenetic and probably
genetic tools (Telerman and Amson 2009).
It can be concluded that both cell-autonomous events
(genetic perturbations) and actions of environment may
contribute to carcinogenesis. The former are random,
while the latter are, most likely, non-random and depend
on the genetic constitution of the organism, that is, on a
multitude of factors, some of which may have no explicit
relation to carcinogenesis (e.g. genetic predisposition to
inflammatory reactions, senescence-associated secretory
phenotype, etc.).
One can envision the internal organization of the cell and
organism as complex hierarchy of densely interlaced
molecular networks with an abundance of feedback loops.
The tumor is so strongly integrated into these networks
(Albini and Sporn 2007; Allinen et al. 2004; Balkwill 2004;
Bissell and Radisky 2001; Gallagher et al. 2005; Hill et al.
2005), that it is impossible to “isolate” and consider it with
no connections with its environment, exactly as in the case
of any other tissue. Cooperation between tumor and its
environment is well established, what allows to consider a
tumor like a special “organ” (Bissell and Radisky 2001).
Indeed, a tumor meets the formal definition of an organ as
an anatomically discrete complex of tissues, integrated to
perform specific functions and has the necessary attributes:
stem cells (cancer stem cells [CSC]) (Reya et al. 2001),
hierarchical structure often simulating a normal tissue
constitution (Perez-Losada and Balmain 2003), cellular
specialization (Axelrod et al. 2006), structural and func-
tional unity with the microenvironment (Albini and Sporn
2007; Merlo et al. 2006), and, as has been noted above, a
specific function – the organism death (Lichtenstein
2005a). Tumors produce both stimulators and inhibitors of
angiogenesis in their microenvironment and exhibit a
growth slowdown with a possible asymptotic approach to
a final tumor size, or “set point”, what indicates that the
tumor maintains a vestige of normal tissue mass control.
Developing tumors and organs may share an awareness of
total mass through the exertion of an increasingly inhibitory
influence on their own growths by way of increased natural
angiogenic suppression. The difference is that the “set
point” has been inappropriately set forward, allowing the
tumor to kill the host well before the new set point is
achieved (Hahnfeldt et al. 1999).
While the tumor/host relationships were earlier thought
to be antagonistic (perhaps by analogy with infections),
today their synergy (paradoxical “love, not war”) becomes
apparent (Lichtenstein 2008). In its destructive efforts, the
tumor relies on the support of normal tissues, both the
immediately surrounding (Albini and Sporn 2007; Bissell
and Radisky 2001; Dranoff 2004) and remote (Dolloff et al.
2007; Hayward et al. 2001; Hiratsuka et al. 2006; Kaplan et
al. 2005; Karnoub et al. 2007; Nolan et al. 2007; Sawyers
2007; Williams et al. 2007; Wyckoff et al. 2007). The
participants of the “rescue operation” include fibroblasts
(Elenbaas and Weinberg 2001; Kalluri and Zeisberg
2006;O r i m oe ta l .2005), tumor-associated macrophages
(Condeelis and Pollard 2006;P o l l a r d2004;S a h a i2007),
tumor-infiltrating neutrophils (Ardi et al. 2007), stroma
(Albini and Sporn 2007), bone marrow (Nolan et al.
2007), remote organs (Hiratsuka et al. 2006). Owing to the
help from the outside, the tumor gets blood supply, grows,
has an increased mutation rate (Gupta and Massague
2006; Sahai 2007). In cell invasion experiments, it was
found that stroma fibroblasts can lay tracks in the
intercellular matrix and serve as leaders for epithelial
cells that followed them (Gaggioli et al. 2007). Using
animal models of breast cancer metastasis, it was shown
that there exist subpopulations of macrophages that
provide for tumor cell extravasation, survival and subsequent
growth of metastatic cells (Qian et al. 2009). Bone marrow
cells exposed to cytokines secreted by the tumor migrate to
target organs and prepare the niche for future metastases
(Kaplan et al. 2005). The enzyme lysyl oxidase secreted by
hypoxic tumor cells was found to modify the extracellular
matrix and also contribute to pre-metastatic niche formation
(Erler et al. 2009). These findings are supported by gene
expression profiling of both epithelia and stroma at specific
time points during tumor progression, which reveal sequen-
tial enrichment of genes mediating discrete biologic func-
tions in each tissue compartment (Reuter et al. 2009).
The complex interactions between normal and tumor cells
resultinformationofnumerous“viciouscircles”thatdrivethe
tumor progression. Though microenvironment sometimes
reveals “yin-yang” activities, i.e. can be, depending on
circumstances, either pro- or anti-carcinogenic (Wang et al.
2004; Witz 2008), the net balance steadily develops in favor
of the growing tumor.
90 Clin Epigenet (2010) 1:85–100The role in carcinogenesis of the immune system, the
main defender of the organism from all invasions, is dual.
At the initial stages, the adaptive immunity maintains occult
cancer in an equilibrium state (Koebel et al. 2007).
However, after the clone escape and tumor formation the
immune system begins paradoxically to stimulate its
development (Balkwill and Mantovani 2001; de Visser et
al. 2006; Prehn 1994).
Thus, the oncologic process appears as program of
systemic disintegration with a role of the tumor as its
organizer, coordinator and pacemaker.
Why does the cancer patient die?
The question of how and why a tumor kills the organism,
owing to its importance, should apparently take the central
place in cancer research: its solution could help, on the one
hand, to get at the root of this disease, and on the other, to
find effective treatment. Strangely enough, this question
does not attract the attention it deserves, and a host of
questions remain. Why the death of the cancer patient is
inevitable? Whether is it a side effect of tumor growth, a
result of exclusively local influence on normal tissues? Or,
on the contrary, is the death predetermined and caused by a
certain special activity of the cancer cell, is “beneficial” and
for that very reason so evolutionary conservative?
The point of view that the tumor kills by the fact of
its existence seems to be self-evident (metastases, in
particular, are considered to be an exhaustive explanation
of the fatal outcome). This viewpoint is based probably
on the fact that in vitro cultured cancer cells do not exert
a negative effect on their normal neighbors, do not
produce toxic products and, most likely, are not capable
of doing them in vivo. At the same time, their ability to
spread and form metastases is obvious. It seems natural
that it is the local effects on surrounding normal tissues
that cause death of the body. In some particular cases,
this is what happens indeed: local effects prevail, for
example, in cases of profuse bleedings, brain compres-
sion, intestine perforation or obturation, etc.
However, malignant tumor evidently exerts also a general
influence on the organism. A situation of a “silent” tumor is
known, for example, when there is a clinical picture of an
oncologic disease but no primary locus can be found (in other
words, there exist generalized manifestations but local ones
are absent). The loss of weight by oncologic patients long
beforetheyarediagnosed(Grosvenoretal.1989; Kritchevsky
et al. 1991) speaks in favor of the same. The tumor growth
leads to incompatible with life disturbance in the body
homeostasis, which manifests itself in diverse paraneoplastic
syndromes affecting almost every organ and tissue of the
body (Finora 2003; Kim et al. 2003;P o s n e r2003;S a t oe ta l .
2003; Tisdale 2002; Yamada et al. 2003).
A solid tumor weighting 1, 10 and 100 g results in initial,
expressedand heavyclinicalsymptoms, respectively.Itseems
likely that such negligible mass should not have, in itself, any
specific consequences, as is the case with benign tumors of
even larger mass. Drastic discrepancy between apparent
negligibility of the cause and gravity of the effects suggests
that the malignant tumor is endowed with a special killer
function (Lichtenstein 2005b, 2008). Owing to its universal-
ity, this function deserves to be added to the other hallmarks
of cancer (Hanahan and Weinberg 2000). The killer function
is a resumptive notion, which designates the ability of cancer
to kill an organism (no matter how). Its special case is
cachexia (the cause of death of ~20% of cancer patients),
which is the most demonstrative example of distant and
generalized influence of cancer on the body (Tisdale 2002).
The cancer cell is obviously not capable of producing
any toxins or doing something that the normal cell is unable
to do at some stage of its development (after all, they both
have the same genome). Since animal cells produce a host
of various biologically active compounds (cytokines,
c h e m o k i n e s ,R O S ,e t c . ) ,i ti sp o s s i b l et oa s s u m et h e
following general mechanism of the killer function: cancer
cells, possessing an ordinary set of instruments, use them in
unusual combinations and/or concentrations, or at inade-
quate times and/or place, what brings about incompatible
with life disturbances of the homeostasis. For example, the
cytokine MIC-1 produced by many tumors is capable of
inducing, via central mechanisms, anorexia and loss of
weight (Johnen et al. 2007). The cachexia observed in
many cancer patients is also due to the factors secreted by
the tumor or its environment: (1) increased lipolysis is
induced by lipid-mobilizing factor; (2) tissue catabolism is
partially mediated by cytokine TNF-α as well as interleukins
(IL)-1 and IL-6; (3) proteolysis-inducing factor directly
stimulates tissue breakdown (Tisdale 2002). The comprehen-
sive gene expression profiles of each cell type composing
normal breast tissue and breast carcinomas demonstrates that
extensive gene expression changes occur in all cell types
during cancer progression and that a significant fraction of
altered genes encode secreted proteins and receptors (Allinen
et al. 2004).
The accepted paradigm does not explain the existence of
killer function of cancer cell. It is impossible to understand
why the appearance of a comparatively small cellular mass,
regardless of its type and localization, inevitably kills the
entire body (especially in view of the fact that benign
tumors may sometimes be as large as several kilograms
without deleterious consequences). Death of the body and
preceding period of progressive decay are viewed by the
accepted paradigm as a self-evident result of tumor growth.
But stating a cause–effect relation between two events
(tumor growth and body death) is not the same as
explaining it. In the accepted paradigm, the indomitable
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and counter-productive (for some unknown reason, cancer
cells always strive for self-destruction).
The new paradigm offers a simple explanation for this
phenomenon: the cancer cells kill the organism because
they have been created just for this purpose; the evolution
having created these killers has thereby solved some
problems of top priority (see above).
Tumorigenesis as differentiation
The notion of a malignant tumor as a specialized organ
has received an additional support with the discovery of
CSCs (Reya et al. 2001; Shackleton et al. 2009). The
concept of CSC traces back, as was repeatedly noted, to
the 150-year-old “embryonal rest” theory of cancer by
Virchow, Cohnheim and Durante. Based on the similarity
between cancer cells and embryonic cells, it is supposed
that the tumor arises from stray embryonic cells present in
an adult organism. Usually dormant, they are capable of
waking up under the influence of various irritants, mainly
inflammation, and giving rise to a tumor (Coussens and
Werb 2002; Hendrix et al. 2007).
Current molecular and genetic data are also indicative of
a similarity between cancer and embryonic cells (Strizzi et
al. 2009). Thus, the transcriptional module characteristic of
embryonic stem cells is activated in many cancer cells
(Wong et al. 2008). Proceeding from Virchow’s statement
that tumors grow by the same laws that govern embryonic
development, the authors of a recent work tried to find out
to what degree tumor transcriptome corresponds to that of
developing tissues. Indeed, they have observed common
global trends of gene expression (Naxerova et al. 2008). A
common property of many tumors is the expression of C/T
(cancer/testis) antigens (Simpson et al. 2005), which
suggests an awakening in cancer cells of the transcription
program inherent in germ cells and forming a standard
malignant phenotype (immortality, immune evasion, ability
to invade and metastasize, genome hypomethylation) (Old
2001).
Based on these data, a theory was advanced according
to which a tumor has stem cells which are in many
respects similar to normal ones: both possess the ability
of self-renewal and differentiation (achieved by asymmetric
division), plasticity, unlimited proliferation, ability to
recreate the tissue de novo, activity of main regulators
of embryonic development (Clarke and Fuller 2006;
Hendrix et al. 2007;P o s t o v i te ta l .2007;S p a r m a n na n d
van Lohuizen 2006). Normal mammary epithelial stem
cells and breast cancer stem cells display a decreased
expression of some specific microRNAs, restraining their
clonogenic and tumor-initiating activities, respectively.
Apparently, stem cell regulatory pathways are the same
as cancer stem cell regulatory pathways (Dirks 2009;
Shimono et al. 2009).
The CSC concept assumes the hierarchical structure of a
tumor. The most important are CSCs, which make probably a
very small fraction of the whole cell population (sometimes,
their quantityissubstantiallyhigher; Adamsetal.2007;K e l l y
et al. 2007) and may vary in tumors of different origin
(Kennedy et al. 2007). This small subpopulation governs
growth of the tumor and its dissemination (Hermann et al.
2007, 2008), its selective eradication is capable, as was
shown in a model system, of suppressing the growth of the
tumor and its metastases (Gupta et al. 2009a). The bulk of
the tumor consists of differentiated non-CSCs destined for
final death and unable to recreate a tumor de novo. However,
constituting the majority, non-CSCs determine the clinical
picture of the disease.
The CSC concept is important in many respects. It
allows us to explain difficulties of the present-day chemo-
therapy (stem cells possess special properties, being, in
particular, more resistant to chemotherapeutic drugs)
(Gupta et al. 2009a) and aim at new targets. On the other
hand, this concept prompts one to reconsider the existing
notion about tumorigenesis: to depart from the idea of the
chaotic process of trial-and-error type and to consider it as a
well familiar cell differentiation—a set of irreversible,
deterministic transitions from one stable state to another
(namely, the path from pluripotent CSC to differentiated
non-CSCs) (Gupta et al. 2009b). As the very notion of
“stemness” assumes the ability of the cell to differentiate,
identification of the cancer analogue of normal stem cell
suggests a corresponding interpretation: just as normal stem
cells differentiate into phenotypically diverse progeny with
limited proliferative potential, cancer stem cells also
undergo epigenetic changes analogous to the differentiation
of normal cells, forming phenotypically diverse nontumori-
genic cancer cells that compose the bulk of cells in a tumor
(Shackleton et al. 2009). In other words, carcinogenesis is
probably not “an illness of differentiation” as usually
thought, but a special differentiation, during which the
cancer cell co-opts standard, ready-to-use modules: the
epithelial–mesenchymal transition (Polyak and Weinberg
2009), aerobic glycolysis (Christofk et al. 2008), angiogenic
switch (Bergers and Benjamin 2003), immune evasion and
immunity suppression (Kim et al. 2006).
The view of tumorigenesis as a differentiation means to
some extent the return to the early Virchow’s notion.
Probably, cancer progenitor cells (Feinberg et al. 2006) are
initially present in the body. Staying in a “waiting mode”,
they are steadily exposed to internal and external mutagens
what results in a gradual erosion of the system of checks-
and-balances (protooncogenes and suppressor genes) and,
eventually, activation of the cryptic “cancer differentiation”.
The fact that precancerous stem cells are capable of
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and benign directions (Chen et al. 2007) indicates that there
are bifurcations in development pathways that route cells
along pre-determined trajectories to the alternative states,
the normal and cancer phenotypes (Fig. 1). The balance
between these alternative pathways apparently depends on
association of the stem cell with the niche (Clarke and
Fuller 2006; Li and Neaves 2006; Walkley et al. 2007).
Mutations, inflammation and other factors can damage this
association and favor the choice of the cancer pathway.
Indeed, imaging of hematopoietic precursor division in real
time has shown that the balance between symmetric and
asymmetric divisions is responsive to extrinsic and intrinsic
cues and, in particular, to oncoproteins (Wu et al. 2007).
One of the most discussed subjects is the origin of CSC—
whether they arise directly from normal stem cells or from
cellsinitiallymoredifferentiatedbuthavingacquiredstemcell
properties for the second time (Bjerkvig et al. 2005; Clarke
and Fuller 2006; Kennedy et al. 2007; Perez-Losada and
Balmain 2003). Apparently, both scenarios can take place. In
some cases (bronchioalveolar stem cells, prostate luminal
epithelial stem cells, intestinal crypt stem cells), by means of
genetic lineage-marking it has been shown that normal stem
cells are the cells of origin for corresponding types of cancer
(Barker et al. 2009; Kim et al. 2005;W a n ge ta l .2009;Z h u
et al. 2009). On the other hand, recent data obtained on the
model of immortalized human mammary epithelial cells
(both normal and transformed), have demonstrated an
unexpected linkage between the epithelial–mesenchymal
transition, a key developmental program, and acquisition of
stem cell properties (Mani et al. 2008). Such a backward
movement (from more to less differentiated state) suggests a
principal possibility of CSC development from non-CSC
(Gupta et al. 2009b). This suggestion is in agreement with a
hypothesis that stemness is a property of systems, rather than
cells. A system with stemness can achieve a controlled size,
maintain itself homeostatically, regenerate when necessary
and do so by using feedback control. It suggests that under
different conditions different cell types can assume the role
of “cancer stem cells” (Lander 2009).
The genetics and epigenetics of carcinogenesis
Two types of changes contribute to carcinogenesis: genetic
(damages of the primary structure of DNA—point mutations,
deletions, insertions, chromosome instability) (Tomlinson et
al. 1996;W o o de ta l .2007) and epigenetic (changes in the
numerous gene regulatory mechanisms—DNA methylation,
chromatin modification, microRNA regulation, mRNA pro-
cessing) (Baylin and Ohm 2006; Esquela-Kerscher and Slack
2006; Feinberg 2007; Lotem and Sachs 2002;M a y ra n d
Bartel 2009).
Thus, within one process (carcinogenesis), two
opposite principles coexist: the chaotic (mutagenesis)
and highly regulated (epigenesis). Mutations are local,
rare, random, and arise in individual cells (i.e. mono-
clonal). Epigenetic events, on the contrary, are large-
scale, cover the entire genome, coordinate many
subsystems, are initiated at embryogenesis and unfold
throughout the life (Bernstein et al. 2006;H ee ta l .2007;
Jones and Baylin 2007; Klose and Bird 2006). Epigenetic
imprints that lead to cancer are inheritable (Bird 2007),
arise early (Fraga et al. 2005), often at the stage of
preclinical changes (Jacinto et al. 2007; Sempere et al.
2007), affect simultaneously many cells (are polyclonal)
( F e i n b e r ge ta l .2006) and have the deterministic nature
(Gazin et al. 2007;K e s h e te ta l .2006;M a y ra n dB a r t e l
2009; Widschwendter et al. 2007). The methylation of
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Fig. 1 Normal vs. cancer bifurcations in differentiation pathways.
Pluripotent stem cells differentiate to form either normal or cancer
stem cells (SC or CSC, respectively). By default, normal stem cell
differentiation is active, while cancer differentiation is blocked by
several tissue-specific barriers. As the barriers are removed by
mutations or some environmental cues, cancer stem cells become
gradually activated and the cryptic program is brought into action in a
step-by-step manner. As a result, “differentiated” tumor cells are
formed. a Carcinogenic program is blocked. b, c Gene mutations
sequentially remove the barriers and make “differentiation leaps”
possible. The numbers denote rate-limiting events (mutations) that are
required to pass the differentiation stages. The gradual darkening of
cells represents their acquisition of a cancer phenotype. Lightning
arrows, mutations; arrows, passage possible; ⊥, block of cancer
differentiation. (Reprinted from A.V. Lichtenstein (2008) Cancer: shift
of the paradigm, Med Hypotheses, 71(6):839–850, with permission
from Elsevier)
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most likely imprinted in the cell genome (Schlesinger et
al. 2007). The complex coordination of epigenetic events
suggests their programmed character (Baylin and Ohm
2006; Jones and Baylin 2007). Indeed, recent data suggest
that malignant transformation is a highly cooperative
process, involving synergy at multiple levels of regulation
(McMurray et al. 2008).
As both components are undoubtedly important for
carcinogenesis, a question arises of how they relate to each
other and what is the role of each of them. Answering this
question will allow to find out whether cancer is casual or
regular. The prevailing notion that it is mutagenesis that
leads to cancer assumes the casual character of the latter.
However, in connection with the ongoing reappraisal
(“epigenetics wins over genetics”; Lotem and Sachs
2002), there is a feeling that this phenomenon is pre-
determined. The theory of multistage carcinogenesis and
the ensuing notion of transformation resistance of cells as
the countdown trigger of carcinogenesis (see above) lay the
basis for some assumptions. If one describes cancer
differentiation as a pathway with several roadblocks, then
mutagenesis would serve as a mechanism of taking those
barriers away and step-by-step bringing this cryptic
program into action: it manifests itself in outward appear-
ance as successive precancerous tissue lesions (Fig. 1).
The transformation resistance of normal individuals is
evolutionary adjusted in such a way as to postpone tumor
appearance to post-reproductive period. Since the resistance
of individuals with germ-lin em u t a t i o n si sd e c r e a s e d
resulting in a shortened period of carcinogenesis, they
suffer from cancer in the reproductive period of life. This
interpretation can, by the way, explain the differences in the
spectra of hereditary and sporadic tumors with the same
genetic defects (Fig. 2).
Thus, the allocation of functions between mutagenesis
and epigenetics during carcinogenesis looks as follows: the
former is the driving force of “cancer differentiation”,
whereas the latter is the mechanism of its implementation
(Lichtenstein 2008). The acquisition by the cancer cell of
the necessary functional modules is achieved by means of
genomereprogramming withthe use of epigeneticmachinery.
The epigenetic memory provides the inheritance of the
acquired properties by generations of transformed cells (Ting
et al. 2006).
DNA methylation
Recent evidence indicates that epigenetic changes might
“addict” cancer cells to altered signal-transduction path-
ways during the early stages of tumor development (Baylin
and Ohm 2006). DNA methylation pattern undergoes the
most significant changes (Baylin et al. 1998; Esteller et al.
2001; Jones and Baylin 2002; Toyota and Issa 1999). In
normal cells, the CpG islands (clusters located in the
regulatory sites of genes) are usually not modified, whereas
single CpG dinucleotides spread over the genome (80% of
the total) are, as a rule, methylated. Tumor cells undergo a
reciprocal change: local hypermethylation of some of the
CpG islands is combined with global genome demethyla-
tion (Bernstein et al. 2007). The CpG islands methylation,
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Fig. 2 Mutation-driven cancer differentiation. Tissue-specific trans-
formation resistance of cell (TRC) values are determined, in part, by
different numbers of rate-limiting events (mutations, indicated by
lightning arrows) required for cancer appearance (denoted with ©
symbol). Tissues characterized by a low risk of cancer (low mass, low
proliferation) are characterized by a low number of rate-limiting
events and, consequently, by relatively big “differentiation leaps”
shown as differently colored arrows (tissues (a) and (b)). On the
contrary, the high risk of tissues with a large mass and active
proliferation is offset by a greater number of mutations and a relatively
smaller impact of each of them to differentiation (tissues (d) and (e)).
A The TRC values of different tissues have been adjusted during
evolution so that sporadic cancers arise mainly in the post-
reproductive period of life (or do not arise at all). B A germ-line
mutation in specific gene (red color) reduces the TRC value of all
cells in the body, but to a different degree: to a greater degree in
tissues (a) and (b), and to a lesser degree in tissues (d) and (e). In
tissue (c), the “red” gene is not involved in carcinogenesis and its
mutation is not manifested. As a result, there is a high probability of
multiple tumors in individuals of reproductive age, and the spectra of
these tumors may differ from those observed for sporadic tumors with
the same genetic defect. Germ line mutations of cancer genes are thus
subject to the purifying selection. (Reprinted from AV Lichtenstein
(2008) Cancer: shift of the paradigm, Med Hypotheses 71(6):839–
850, with permission from Elsevier)
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DNA methyltransferases in cancer cells (De Marzo et al.
1999), leads to gene silencing (a stable inactivation of the
adjacent gene) owing to steric hindrances in the binding of
transcription factors to the promoter as well as histone
hypoacetylation (Stimson and Vertino 2002).
Current data provide evidence for the early occurrence,
universality and nonrandom character of local hypermethyla-
tion (Costello et al. 2000; Luo et al. 2005;M a r t i n - S u b e r oe t
al. 2009). This modification is likely to affect genes,
which in embryonic stem cells are associated with
Polycomb group proteins (these proteins repress cell
differentiation genes) (Ohm et al. 2007; Ohm and Baylin
2007; Schlesinger et al. 2007; Widschwendter et al. 2007).
This fact supports the view that cancer stem cells originate
from normal stem cells, in which the transient repression
of differentiation genes by Polycomb group proteins is
replaced with permanent gene silencing. As a result, these
cells are blocked at a perpetual state of self-renewal
(Widschwendter et al. 2007).
Methylation analysis on a genome-wide scale by means
of a combination of immunoprecipitation of methylated
DNA, microarray technology and bioinformatics has shown
that cancer-related de novo DNA methylation comes about
through an instructive targeting mechanism. De novo
methylated genes possess a number of distinctive properties
(they belong to certain functional classes, have common
sequence motifs in their promoters and cluster location).
Some of them are initially (i.e. still in the normal cells)
inactive, what excludes the possibility that these events may
be subject to growth selection. This instructive mechanism
of de novo methylation in cancer cells is thought to be
similar to that occurring during normal development (Cedar
and Bergman 2009).
In other cases, promoter methylation and gene silencing
confer obvious selective advantages to the cell: for
example, silencing of suppressor genes (in particular, RB1,
VHL, CDKN2A, CDKN2B, CDH1, PTEN) and DNA repair
genes (e.g. MLH1, BRCA1) (Esteller et al. 2001; Jones and
Baylin 2002; Karpf and Matsui 2005; Khan et al. 2004)
results in uncontrolled proliferation and high variability due
to genome instability.
Another prominent feature of cancer cells seen already at
early stages of transformation is the global demethylation of
the genome (Chen et al. 1998; Rainier and Feinberg 1988).
The important role of this epigenetic alteration follows from
data that the demethylating agent 5-aza-2′-deoxycytidine
can transform cell cultures (Rainier and Feinberg 1988),
while chronic dietary methyl deficiency induces hepatocar-
cinogenesis in rodents (Pogribny et al. 1997). In normal
cells, the sequences of compact chromatin are strongly
methylated and functionally repressed. Genome demethy-
lation strongly influences chromatin condensation, expres-
sion, replication schedule, chromosome stability (Karpf and
Matsui 2005; Rodriguez et al. 2006), mutation rate (Chen et
al. 1998).
Recent data have complicated the simple scheme of
“local DNA hypermethylation—global demethylation” in
cancer cells. First, de novo DNA methylation is a non-
autonomous process but is tightly intertwined with other
epigenetic events: modifications of chromatin (in particular,
methylation–demethylation of histones) (Bird 2001; Cedar
and Bergman 2009; Ciccone et al. 2009;E s t e l l e r2007; Vire
et al. 2006), and with small RNA regulation (Lujambio et al.
2007; Lujambio and Esteller 2007;M o a z e d2009). Second,
not only hypermethylation but also demethylation of gene
promoters can be aberrant in cancer cells (Smith et al. 2009).
These modifications affect functionally different groups of
genes, suppressor genes and candidate protooncogenes
(TKTL1, H19, MAGEA2, MAGEA3/6, MAGEA4, MAGEA11,
GPR17, GRIN1, C19ORF28), respectively. As a result, the
former are silenced, while the latter activated. Activation of
these physiologically repressed genes takes place in many
solid human tumors and is carried out with the participation
of transcription factor BORIS (Smith et al. 2009).
Finally, a new approach (comprehensive high-throughput
array-basedrelativemethylation)has allowedthe discoveryof
the so-called CpG island shores. They represent tissue
differential methylation regions and cancer differential
methylation regions (T-DMRs and C-DMRs, respectively),
located at some distance (1–2 kb) from the CpG islands
(Irizarry et al. 2009). The methylation status of these
evolutionary conserved regions (quite similar in man and
mouse) controls the expression of the adjacent genes. In
colorectal cancer, C-DMRs undergo much more signifi-
cant changes than the corresponding CpG islands. The fact
that methylation changes in cancer are at sites that vary
normally in tissue differentiation, is consistent with the
epigenetic progenitor model of cancer. The latter proposes
that epigenetic alterations affecting tissue-specific differ-
entiation are the predominant mechanism, by which
epigenetic changes cause cancer (Feinberg et al. 2006;
Feinberg 2007).
MicroRNA regulation
The most significant discovery of last time is the identifi-
cation of microRNAs, which are involved in negative
regulation of gene expression (Carthew and Sontheimer
2009). These short molecules (20–25 nucleotides long) are
processed from large precursors (pri-miRNAs and pre-
miRNAs) and transported to the cytoplasm. As a part of
RNA-induced silencing complex (RISC), they interact with
partially complementary mRNA sequences at their 3′-
untranslated regions (3′-UTR). The result is translation
inhibition or mRNA degradation. A specific feature of this
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microRNA to interact with numerous targets) and, as a
consequence, a multitude of effects (Carthew and Sontheimer
2009; Esquela-Kerscher and Slack 2006;M aa n dW e i n b e r g
2008). Approx. one thousand microRNAs known today are
supposed to regulate translation of about 30% mRNA,
thereby being involved in all fundamental processes: cell
division, differentiation, apoptosis, etc. For example,
microRNA-200c (miR-200c) inhibits the expression of the
Polycomb gene Bmi-1 (this self-renewal factor sustains stem
cells in postnatal life) and thus prevents both normal and
cancer cells from acquiring stem cell properties (Shimono et
al. 2009).
MicroRNAs play a dual role in carcinogenesis: they may
beeithersuppressorsoroncogenes.EventhesamemicroRNA
may play such a role: for instance, miR-221 and miR-222
target an oncogene, KIT, and therefore function as tumor
suppressors in erythroblastic cells, but they target a number
of tumor suppressors and function as oncogenes in various
human solid tumors (Croce 2009). A decrease in certain
microRNAs as a result of mutations, deletions or epigenetic
silencing may inhibit the expression of suppressor genes
indirectly, for example, via ensuing activation of DNA
methyltransferase genes. Being important epigenetic media-
tors, microRNAs are, in their turn, under epigenetic control:
promoters of their genes in cancer cells are often methylated
(Croce 2009).
A number of observations indicate an instructive character
of microRNA regulation in carcinogenesis. For instance,
using a mouse model of multistage tumorigenesis, involving
the stepwise transformation of pancreatic islet β cells into
pancreatic neuroendocrine carcinomas, and high-throughput
microRNA profiling, it was found that microRNA dynamics
in the stages of tumorigenesis correlate with hallmark
capabilities of cancer (i.e. a distinct microRNA expression
signature corresponds to each of the investigated stages). An
important example is the coupling of metastases with down-
regulation of the miR-200 family, which interferes, as was
mentioned above, with acquisition by cells of stem cell
properties (Olson et al. 2009). Some microRNAs (in
particular, miR-10b, miR-31, miR-182) are able to control
different stages of formation of metastases (Hurst et al.
2009).
Anotherstrikingphenomenonisthewidespreadshortening
in cancer cells of 3′-UTRs of mRNAs by alternative cleavage
and polyadenylation (APA) (Mayr and Bartel 2009). This
is probably a mechanism used by tumor cells, by which
“cancer-associated” genes escape microRNA-mediated
silencing (de Lopez et al. 2007). Since shorter mRNA
isoforms usually exhibit increased stability and produce
tenfold more protein, the high incidence of APA in cancer
cells suggests its important role in oncogene activation
without genetic alteration.
Perspective
The new visionof cancer as natural phenomenon(programmed
death of the organism) has a direct relation to current
research, particularly to choosing directions of future
investigations and treatment strategies. It explains, on one
hand, great difficulties in treating cancer and, on the other
hand, brings to the forefront apparently the most important
property of the cancer cell, namely its killer function, the
mechanism of which remains largely unknown. The situation
in oncology is similar today to that in gerontology, where as
yet “no hypothesis has emerged that yields a useful definition
of dying of old age in terms of cell and tissue biology” and
“the accumulated data fail to provide any clue as to the
mechanism” (Rando 2006).
Meanwhile, the now existing high-throughput approaches
to serial measurement of global gene expression could have
offeredageneralpictureoftheeventsthatunfoldinthetumor-
bearing organism. Such research could show what cell
systems and metabolic pathways and in what tissues undergo
most significant changes under the influence of a growing
tumor, and to what extent these changes are universal for
varioustypesofcancer.Thereby,itwouldbepossibletogetan
insight into the biochemistry of the cancer-induced
programmed death of organism.
Targeted therapy is now considered to be the most
promising approach of combating cancer. It is supposed that
“the promise of targeted therapies will be realized as our
understanding of cancer biology continues to improve” (Hait
and Hambley 2009). In reality, however, the known achieve-
ments along this line seem rather an exception than the rule
and, moreover, there are serious doubts about the possibility
to use targeted therapy as the main and sole means for
elimination of cancer (Hambley and Hait 2009). Indeed, the
differences between the normal and cancer cells are so small,
numerous and evasive that the invention of “a magic bullet”
that would hit all cancer cells and nothing except them does
not seem feasible. For these reasons, modern chemotherapy
is nothing but a medical version of “friendly fire”.I ts e e m s
likely that this situation will remain so until the search of
targets will be limited exclusively to the cancer cell itself.
A deeper understanding of the killer function mechanism
could help changing the situation. It is most likely that this
function is accomplished by means of some peculiarities of
the cancer cell secretome (see above). In such situation, an
“intercepting therapy” aimed at neutralization of cancer cell
rather than its destruction, might be effective. In model
systems, this approach has proved to be promising:
antibodies to VEGFR1 and VEGFR2 inhibit the formation
of metastases in mice, in which VEGFR1- and VEGFR2-
positive bone marrow cells participate in formation of
premetastatic niche (Kaplan et al. 2005); antibodies to
MIC-1 prevent cachexia in mice with xenografted prostate
96 Clin Epigenet (2010) 1:85–100tumors (Johnen et al. 2007); antibodies to interleukin-23
enhance the immune response and protect the animals from
chemical carcinogenesis (Langowski et al. 2006). As the
killer function is only inherent, apparently, in cancer cells,
its elimination will hardly invoke any strong side effects,
this “Achilles’ heel” of the present-day chemotherapy.
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